Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

The FDA approved multiple groundbreaking treatments in July, enhancing options across patient populations. The FDA maintained its momentum in July, issuing a wave of drug approvals across diverse ...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that Health Canada has granted a marketing ...

The following are notable drug approvals for July 2025.

Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating ...

Astria will receive $16m upfront and is eligible for a further $16m in commercialisation and sales milestones.

Astria took the candidate, a monoclonal antibody inhibitor of plasma kallikrein called navenibart, into a late-stage study off the back of a phase 1b/2 trial last year that tied the drug to up to a 92 ...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it has exclusively ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista ...

A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to ...

The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.